Nov 13, 2019
SmartTRAK, the leading provider of market data and analysis for the wound and regenerative medicine markets, recently reported on current trends and the focus on differentiation in the wound care space. The report noted that Biologics is garnering attention through...
Mar 6, 2019
Reapplix has elected additional board members to support and accelerate the company’s development. The newly elected board members bring substantial international competencies and comprehensive experience within business development, commercialisation, funding,...
Jan 17, 2019
A UK self-employed driver and mechanic faced amputation but his ulcer healed and his leg was saved. Philip Herbert is 54 years old and was diagnosed with diabetes type-2 in 2007. He says “I’d been told that I was going to have my foot taken off and because I have a...
Sep 28, 2018
Based on the positive clinical results documented in the outcome data (recently published in The Lancet Diabetes & Endocrinology) of a major international randomized controlled trial of our LeucoPatch® wound healing technology, Reapplix’s primary focus now shifts...
Dec 13, 2017
MD, PhD Magnus Löndahl one of 4 principal investigators of the large randomized controlled trial of LeucoPatch/3C Patch on diabetic foot ulcers presented “Clinical experiences with LeucoPatch and status of the large RCT: Leucopatch™ System in the Management of...
Nov 10, 2017
Data were presented in a poster format and was titled: “3C Patch derived autologous immune cells delivers immune responses appropriate for the treatment of Diabetic Foot...
